Schöffski, P., Mir, O., Kasper, B., Papai, Z., Blay, J., Italiano, A., . . . Gelderblom, H. (2020). Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'. European journal of cancer, 134, . https://doi.org/10.1016/j.ejca.2020.04.021
Chicago-Zitierstil (17. Ausg.)Schöffski, Patrick, et al. "Activity and Safety of the Multi-target Tyrosine Kinase Inhibitor Cabozantinib in Patients with Metastatic Gastrointestinal Stromal Tumour After Treatment with Imatinib and Sunitinib: European Organisation for Research and Treatment of Cancer Phase II Trial 1317 'CaboGIST'." European Journal of Cancer 134 (2020). https://doi.org/10.1016/j.ejca.2020.04.021.
MLA-Zitierstil (9. Ausg.)Schöffski, Patrick, et al. "Activity and Safety of the Multi-target Tyrosine Kinase Inhibitor Cabozantinib in Patients with Metastatic Gastrointestinal Stromal Tumour After Treatment with Imatinib and Sunitinib: European Organisation for Research and Treatment of Cancer Phase II Trial 1317 'CaboGIST'." European Journal of Cancer, vol. 134, 2020, https://doi.org/10.1016/j.ejca.2020.04.021.